Title:
METHODS OF TREATING CHEMOTHERAPY OR RADIOTHERAPY INDUCED NEUTROPENIA
Document Type and Number:
WIPO Patent Application WO/2021/112654
Kind Code:
A1
Abstract:
Provided herein are methods of treating chemotherapy-induced neutropenia in a patient in need thereof by administering to the patient an effective amount of Eflapegrastim. Also provided herein are methods of treating radiation-induced neutropenia in a patient in need thereof by administering to the patient an effective amount of Eflapegrastim.
More Like This:
| WO/2008/014220 | VACCINE IMMUNOTHERAPY |
| WO/2023/204693 | COMPOSITION FOR REDUCING SIZE OR VOLUME OF TARGET TISSUE OR KIT INCLUDING SAME |
| WO/2022/184825 | COMPOSITIONS FOR EX VIVO ORGAN CARE |
Inventors:
CHOI JAE HYUK (KR)
KIM EUN JUNG (KR)
KIM YU YON (KR)
LEE GYU HYAN (KR)
HAN HYESUN (KR)
KIM EUN JUNG (KR)
KIM YU YON (KR)
LEE GYU HYAN (KR)
HAN HYESUN (KR)
Application Number:
PCT/KR2020/017798
Publication Date:
June 10, 2021
Filing Date:
December 07, 2020
Export Citation:
Assignee:
HANMI PHARM IND CO LTD (KR)
International Classes:
A61K38/19; A61K45/06; A61P35/02
Domestic Patent References:
| WO2019152530A1 | 2019-08-08 |
Other References:
ANONYMOUS: "Abstract 1347: In vivo efficacy of eflapegrastim in rats with chemotherapy-induced neutropenia", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 77, no. Suppl. 13, 1 July 2017 (2017-07-01), US, pages 1347, XP093104859, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2017-1347
SCHWARTZBERG LEE S. ET AL: "Eflapegrastim, a novel and potent long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 37, no. 15, Suppl., 20 May 2019 (2019-05-20), US , pages 539, XP093104871, ISSN: 0732-183X, DOI: 10.1200/JCO.2019.37.15_suppl.539
VACIRCA JEFFREY L., CHAN ARLENE, MEZEI KLÁRA, ADOO CLARENCE S., PÁPAI ZSUZSANNA, MCGREGOR KIMBERLY, OKERA MEENA, HORVÁTH ZSOLT, LA: "An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer", CANCER MEDICINE, JOHN WILEY & SONS LTD., GB, vol. 7, no. 5, 1 May 2018 (2018-05-01), GB, pages 1660 - 1669, XP055819786, ISSN: 2045-7634, DOI: 10.1002/cam4.1388
SCHWARTZBERG L, BHAT G, MEZEI K, LANG I, MOON YW, SENVIRATNE L, CHAWLA S, COBB P, YANG Z: "Abstract P1-13-05: Efficacy and safety of eflapegrastim confirmed in reducing severe neutropenia in breast cancer patients treated with myelosuppressive chemotherapy in the second Phase 3 randomized controlled multinational trial compared to pegfilgrastim (RECOVER trial)", vol. 79, no. S4, 15 February 2019 (2019-02-15), pages 1 - 4, XP009528399, ISSN: 0008-5472, DOI: 10.1158/1538-7445.SABCS18-P1-13-05
BARRETT JOHN A.; CHOI JAEHYUK; LAKSHMIKANTHAN SRIBALAJI; KIM YU-YON; GREENE DOUGLAS; KOLLI PRASAD; SONG TAE HUN; CHOI IN YOUNG; KI: "Eflapegrastim's enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing", EXPERIMENTAL HEMATALOGY, ELSEVIER INC., US, vol. 92, 29 September 2020 (2020-09-29), US, pages 51 - 61, XP086405315, ISSN: 0301-472X, DOI: 10.1016/j.exphem.2020.09.199
YU-YON KIM, EUNJUNG KIM, HYESUN HAN, SEUNGJAE BAEK, SHANTA CHAWLA, PRASAD KOLLI, GAJANAN BHAT AND FRANCOIS LEBEL: "Abstract 2044: Chemotherapy induced neutropenia in rats following administration of eflapegrastim or pegfilgrastim on the same day at three timepoints and at 24 hours post-chemotherapy", CANCER RESEARCH / AACR ANNUAL MEETING 2020, vol. 80, no. 16, 15 August 2020 (2020-08-15), XP009528398, DOI: 10.1158/1538-7445.AM2020-2044
SCHWARTZBERG LEE S. ET AL: "Eflapegrastim, a novel and potent long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 37, no. 15, Suppl., 20 May 2019 (2019-05-20), US , pages 539, XP093104871, ISSN: 0732-183X, DOI: 10.1200/JCO.2019.37.15_suppl.539
VACIRCA JEFFREY L., CHAN ARLENE, MEZEI KLÁRA, ADOO CLARENCE S., PÁPAI ZSUZSANNA, MCGREGOR KIMBERLY, OKERA MEENA, HORVÁTH ZSOLT, LA: "An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer", CANCER MEDICINE, JOHN WILEY & SONS LTD., GB, vol. 7, no. 5, 1 May 2018 (2018-05-01), GB, pages 1660 - 1669, XP055819786, ISSN: 2045-7634, DOI: 10.1002/cam4.1388
SCHWARTZBERG L, BHAT G, MEZEI K, LANG I, MOON YW, SENVIRATNE L, CHAWLA S, COBB P, YANG Z: "Abstract P1-13-05: Efficacy and safety of eflapegrastim confirmed in reducing severe neutropenia in breast cancer patients treated with myelosuppressive chemotherapy in the second Phase 3 randomized controlled multinational trial compared to pegfilgrastim (RECOVER trial)", vol. 79, no. S4, 15 February 2019 (2019-02-15), pages 1 - 4, XP009528399, ISSN: 0008-5472, DOI: 10.1158/1538-7445.SABCS18-P1-13-05
BARRETT JOHN A.; CHOI JAEHYUK; LAKSHMIKANTHAN SRIBALAJI; KIM YU-YON; GREENE DOUGLAS; KOLLI PRASAD; SONG TAE HUN; CHOI IN YOUNG; KI: "Eflapegrastim's enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing", EXPERIMENTAL HEMATALOGY, ELSEVIER INC., US, vol. 92, 29 September 2020 (2020-09-29), US, pages 51 - 61, XP086405315, ISSN: 0301-472X, DOI: 10.1016/j.exphem.2020.09.199
YU-YON KIM, EUNJUNG KIM, HYESUN HAN, SEUNGJAE BAEK, SHANTA CHAWLA, PRASAD KOLLI, GAJANAN BHAT AND FRANCOIS LEBEL: "Abstract 2044: Chemotherapy induced neutropenia in rats following administration of eflapegrastim or pegfilgrastim on the same day at three timepoints and at 24 hours post-chemotherapy", CANCER RESEARCH / AACR ANNUAL MEETING 2020, vol. 80, no. 16, 15 August 2020 (2020-08-15), XP009528398, DOI: 10.1158/1538-7445.AM2020-2044
Attorney, Agent or Firm:
Y.P.LEE, MOCK & PARTNERS (KR)
Download PDF:
Previous Patent: CONVEYOR-TYPE FOOD MANUFACTURING APPARATUS
Next Patent: BATTERY MODULE, BATTERY PACK, AND VEHICLE
Next Patent: BATTERY MODULE, BATTERY PACK, AND VEHICLE